We then performed mRNA ISH analyses in FFPE tumor samples of HER2-positive BC (n = 21), GC (n = 17) and CRC (n = 13) patients that were already assessed using HER2 IHC and DNA ISH (Table 1). Here, ERBB2 is linked to neoplasm.